Andreas Hallqvist

1.1k total citations
43 papers, 757 citations indexed

About

Andreas Hallqvist is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Andreas Hallqvist has authored 43 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 10 papers in Epidemiology. Recurrent topics in Andreas Hallqvist's work include Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Andreas Hallqvist is often cited by papers focused on Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Andreas Hallqvist collaborates with scholars based in Sweden, Denmark and United Kingdom. Andreas Hallqvist's co-authors include Jan Nyman, Bengt Bergman, Erik Holmberg, Signe Friesland, Rolf Lewensohn, Per Bergström, Ingmar Lax, Jo-Åsmund Lund, Per Albertsson and Stig Palm and has published in prestigious journals such as Journal of Clinical Oncology, Brain Research and Annals of Oncology.

In The Last Decade

Andreas Hallqvist

42 papers receiving 750 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Hallqvist Sweden 15 476 295 256 207 84 43 757
Takuma Nomiya Japan 16 461 1.0× 166 0.6× 148 0.6× 213 1.0× 65 0.8× 47 736
L. Chinsoo Cho United States 7 257 0.5× 169 0.6× 116 0.5× 193 0.9× 45 0.5× 11 537
K. Pigott United Kingdom 14 509 1.1× 455 1.5× 337 1.3× 127 0.6× 30 0.4× 24 863
Guang Li China 16 384 0.8× 149 0.5× 406 1.6× 97 0.5× 79 0.9× 60 770
Keun‐Yong Eom South Korea 18 280 0.6× 112 0.4× 212 0.8× 116 0.6× 94 1.1× 76 754
S. Marcié France 15 337 0.7× 164 0.6× 195 0.8× 283 1.4× 30 0.4× 41 671
Serena Badellino Italy 18 522 1.1× 199 0.7× 238 0.9× 313 1.5× 23 0.3× 50 847
Shozo Okamoto Japan 17 626 1.3× 768 2.6× 149 0.6× 54 0.3× 44 0.5× 36 1.1k
Xindong Sun China 11 342 0.7× 248 0.8× 133 0.5× 118 0.6× 14 0.2× 20 532
Eric Tonndorf‐Martini Germany 13 184 0.4× 178 0.6× 317 1.2× 168 0.8× 47 0.6× 20 658

Countries citing papers authored by Andreas Hallqvist

Since Specialization
Citations

This map shows the geographic impact of Andreas Hallqvist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Hallqvist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Hallqvist more than expected).

Fields of papers citing papers by Andreas Hallqvist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Hallqvist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Hallqvist. The network helps show where Andreas Hallqvist may publish in the future.

Co-authorship network of co-authors of Andreas Hallqvist

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Hallqvist. A scholar is included among the top collaborators of Andreas Hallqvist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Hallqvist. Andreas Hallqvist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sayin, Sama I., et al.. (2025). Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasis. Frontiers in Oncology. 15. 1569517–1569517.
2.
Hallqvist, Andreas, et al.. (2025). 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. Journal of Nuclear Medicine. 66(5). 707–712. 7 indexed citations
3.
Svensson, Johanna, Maria Yhr, Sama I. Sayin, et al.. (2025). Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 75–75. 1 indexed citations
4.
5.
Goldman, Jonathan W., Jacob Sands, Andreas Hallqvist, et al.. (2024). LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.. Journal of Clinical Oncology. 42(16_suppl). TPS8115–TPS8115. 1 indexed citations
6.
7.
Hallqvist, Andreas, Mette Rasmussen, Jonas Scherman, et al.. (2024). Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Radiation Oncology. 19(1). 173–173. 2 indexed citations
8.
Wiel, Clotilde, et al.. (2024). Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis. Frontiers in Oncology. 14. 1396285–1396285. 1 indexed citations
9.
Rohlin, Anna, Maria K. Magnusson, Levent M. Akyürek, et al.. (2023). Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. Frontiers in Oncology. 12. 1073457–1073457. 3 indexed citations
10.
Albertsson, Per, Tom Bäck, Karin Bergmark, et al.. (2023). Astatine-211 based radionuclide therapy: Current clinical trial landscape. Frontiers in Medicine. 9. 1076210–1076210. 49 indexed citations
11.
Svensson, Johanna, et al.. (2023). Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment. Journal of Nuclear Medicine. 64(9). 1456–1462. 16 indexed citations
12.
Wiel, Clotilde, Henrik Fagman, Levent M. Akyürek, et al.. (2022). KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer. Cancers. 14(9). 2063–2063. 16 indexed citations
13.
Ragnarsson, Óskar, et al.. (2022). Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Current Oncology. 29(5). 3494–3498. 5 indexed citations
14.
Hallqvist, Andreas, Lars Jacobsson, Per Karlsson, et al.. (2022). Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy. Journal of Nuclear Medicine. 64(1). 165–172. 5 indexed citations
15.
Hallqvist, Andreas, et al.. (2021). Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines. 9(11). 1570–1570. 9 indexed citations
16.
Nyman, Jan, Andreas Hallqvist, Jo-Åsmund Lund, et al.. (2016). SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiotherapy and Oncology. 121(1). 1–8. 222 indexed citations
17.
18.
Nyman, Jan, Andreas Hallqvist, Ola Brodin, et al.. (2009). Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group. Journal of Thoracic Oncology. 4(9). 373–373. 1 indexed citations
19.
Nyman, Jan, Signe Friesland, Andreas Hallqvist, et al.. (2008). How to improve loco-regional control in stages IIIa–b NSCLC?. Lung Cancer. 65(1). 62–67. 23 indexed citations
20.
Hallqvist, Andreas, et al.. (1996). Studies on the identity of the rat optic nerve transmitter. Brain Research. 706(1). 89–96. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takuma Nomiya Breakdown of academic impact, for papers by L. Chinsoo Cho Breakdown of academic impact, for papers by K. Pigott Breakdown of academic impact, for papers by Guang Li Breakdown of academic impact, for papers by Keun‐Yong Eom Breakdown of academic impact, for papers by S. Marcié Breakdown of academic impact, for papers by Serena Badellino Breakdown of academic impact, for papers by Shozo Okamoto Breakdown of academic impact, for papers by Xindong Sun Breakdown of academic impact, for papers by Eric Tonndorf‐Martini
Rankless by CCL
2026